Cellaris Biotech joined the international CAR-T community at the 9th Annual CAR-TCR Summit Europe, held in London from 24 to 26 February 2026. Our co-founder and Chief Scientific Officer, João Gonçalves, PhD, presented a scientific poster showcasing the company's latest research on lentiviral platforms for in vivo immune cell engineering.
The poster
Titled "Exploring lentiviral platforms for transient and integrative in vivo targeting: Integrative vs non-integrative strategies for tunable CAR persistence", the poster presented experimental data validating Cellaris's Dual Viral Platform Architecture — a system that combines targeted integrative lentiviral vectors (iLV) with non-integrative variants (niLV) to give clinicians fine-grained control over how long an engineered CAR is expressed in the body.
Key findings shared
The presentation highlighted three core results from Cellaris's preclinical programme:
- High targeting fidelity with in vivo delivery — >65% on-target efficacy and <6% off-target infection across HER2+ and GPC3+ models.
- Dose-dependent killing kinetics on HER2+ SKBR3 tumour cells over 96 hours, at multiple effector-to-target ratios.
- Validated safety profile for the non-integrative variant via Nested Alu-PCR, confirming complete absence of genomic integration.
Engineering immune cells directly inside the patient is no longer a thought experiment — our data shows the path to clinical translation is concrete and increasingly de-risked.
What's next
The feedback from peers, clinicians and partners attending the summit is now feeding back into Cellaris's roadmap. Several conversations opened the door to academic and industry collaborations on solid tumour applications, autoimmune indications and next-generation vaccines — all areas where the platform's modularity offers clear advantages.
For deeper technical detail, see our Science page, or get in touch if you'd like to discuss the work directly.
Back to news